Taro Pharmaceutical Industries Ltd. (TARO) News
Filter TARO News Items
TARO News Results
|Loading, please wait...|
Latest TARO News From Around the Web
Below are the latest news stories about Taro Pharmaceutical Industries Ltd that investors may wish to consider to help them evaluate TARO as an investment opportunity.
HAWTHORNE, N.Y., February 28, 2022--Taro Completes Acquisition of Alchemee
Taro Pharmaceutical Industries (TARO) will acquire Alchemee from Galderma.The deal includes Alchemees business as well as its flagship acne care brand Proactiv.
ZUG, Switzerland & HAWTHORNE, N.Y., February 22, 2022--Galderma and Taro Pharmaceutical Industries Ltd. (NYSE: TARO) ("Taro") announced today they have signed a definitive agreement for Taro to acquire Alchemee, formerly The Proactiv Company (TPC), from Galderma. The agreement between Galderma and Taro includes Alchemee’s business and assets around the world, including the Proactiv® brand.
Taro (TARO) delivered earnings and revenue surprises of -23.08% and 2.26%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
HAWTHORNE, N.Y., January 27, 2022--TARO PROVIDES RESULTS FOR DECEMBER 31, 2021
Taro Pharmaceutical (NYSE:TARO) is scheduled to announce Q3 earnings results on Thursday, January 27th, after market close.The consensus EPS Estimate is $0.91 (+37.9% Y/Y) and the…
Is The Market Rewarding Taro Pharmaceutical Industries Ltd. (NYSE:TARO) With A Negative Sentiment As A Result Of Its Mixed Fundamentals?
It is hard to get excited after looking at Taro Pharmaceutical Industries' (NYSE:TARO) recent performance, when its...
HAWTHORNE, N.Y., January 21, 2022--Taro to Announce Third Quarter Results on January 27, 2022
Taro (TARO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
In a report released today, Ram Selvaraju from H.C. Wainwright maintained a Buy rating on Taro Pharmaceutical (TARO – Research Report), with a price target of $75.00. The company's shares closed last Friday at $48.57, close to its 52-week low of $45.00. According to TipRanks.com, Selvaraju has currently 0 stars on a ranking scale of 0-5 stars, with an average return of -24.8% and a 20.6% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as Aquestive Therapeutics, Oncternal Therapeutics, and Inovio Pharmaceuticals. Currently, the analyst consensus on Taro Pharmaceutical is a Moderate Buy with an average price target of $75.00.